^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    BRAF V600

    i
    Other names: BRAF, B-raf proto-oncogene, B-raf proto-oncogene, Serine/threonine kinase, V-Raf murine sarcoma viral oncogene homolog B, Serine/threonine-protein kinase B-Raf, Proto-oncogene B-Raf, BRAF1, RAFB1, B-raf proto-oncogene Serine/threonine-protein kinase, Murine sarcoma viral (V-Raf) oncogene homolog B1, B-raf serine/threonine-protein, 94 KDa B-raf protein, B-RAF1
    Entrez ID:
    673
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Related tests:
    1d
    A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma (clinicaltrials.gov)
    P2, N=93, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed | Phase classification: P1/2 --> P2
    Trial completion • Phase classification
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    tobemstomig (RG6139)
    3d
    CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal Cancer (clinicaltrials.gov)
    P2, N=106, Not yet recruiting, Peking University Cancer Hospital & Institute
    New P2 trial • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    KRAS mutation • BRAF mutation • NRAS mutation • BRAF V600
    |
    Avastin (bevacizumab) • capecitabine • oxaliplatin • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    3d
    TH-CAR-027 for Grade 4 Gliomas (clinicaltrials.gov)
    P1, N=21, Not yet recruiting, Shanghai Tongji Hospital, Tongji University School of Medicine
    New P1 trial
    |
    BRAF (B-raf proto-oncogene) • CD276 (CD276 Molecule) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF V600E • BRAF V600 • NTRK fusion
    3d
    A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration (clinicaltrials.gov)
    P1/2, N=57, Active, not recruiting, Pediatric Brain Tumor Consortium | Trial completion date: Jun 2030 --> Mar 2026 | Trial primary completion date: Mar 2027 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    BRAF V600E • BRAF V600 • BRAF fusion
    |
    Mekinist (trametinib) • Tafinlar (dabrafenib) • hydroxychloroquine
    3d
    JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan (clinicaltrials.gov)
    P3, N=123, Not yet recruiting, Shanghai JMT-Bio Inc.
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • MSI (Microsatellite instability)
    |
    HER-2 positive • BRAF V600E • MSI-H/dMMR • BRAF V600 • BRAF wild-type
    |
    Stivarga (regorafenib) • oxaliplatin • irinotecan • Fruzaqla (fruquintinib) • Lonsurf (trifluridine/tipiracil) • anbenitamab repodatecan (JSKN003)
    4d
    PARERE: PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence (clinicaltrials.gov)
    P2, N=214, Active, not recruiting, Gruppo Oncologico del Nord-Ovest | Trial completion date: Dec 2025 --> Mar 2026
    Trial completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    BRAF V600E • KRAS mutation • NRAS mutation • BRAF V600
    |
    Idylla™ NRAS-BRAF Mutation Test
    |
    Avastin (bevacizumab) • Vectibix (panitumumab) • Stivarga (regorafenib) • oxaliplatin • irinotecan
    4d
    ROMANCE - GOIM: ROMANCE: "Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer" (clinicaltrials.gov)
    P2, N=150, Not yet recruiting, Gruppo Oncologico Italia Meridionale
    New P2 trial • Circulating tumor DNA
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • MAP2K1 (Mitogen-activated protein kinase kinase 1)
    |
    BRAF V600E • BRAF V600
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • irinotecan • Lonsurf (trifluridine/tipiracil)
    4d
    Concomitant RAS and BRAF V600E Mutations in Unresectable Metastatic CRC: A Case of Long-term Survival. (PubMed, J Anus Rectum Colon)
    Moreover, reports on the long-term survival of patients with unresectable mCRC with concurrent mutations are lacking. The present study reports a rare case of long-term survival of over 39 months in a patient with mCRC harboring both RAS and BRAF V600E mutations, where chemotherapy alone was effective without surgical resection of the primary or metastatic lesions.
    Journal
    |
    BRAF (B-raf proto-oncogene) • RAS (Rat Sarcoma Virus)
    |
    BRAF V600E • BRAF V600
    6d
    Evaluating the Molecular Landscape by Multigene Testing in Preoperative BRAF V600E-Positive Thyroid Nodules: A Multicenter Study (ChiCTR2500112247)
    P=N/A, N=400, Not yet recruiting, Renji Hospital, School of Medicine in Shanghai Jiao Tong University, Shanghai; Renji Hospital, School of Medicine in Shanghai Jiao Tong University, Sh
    New trial
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF V600
    6d
    A Real-World Study of Precision Treatment for Advanced Cholangiocarcinoma Based on Molecular Subtyping (ChiCTR2500111407)
    P=N/A, N=55, Not yet recruiting, Fuzhou University Affiliated Provincial Hospital; Fuzhou University Affiliated Provincial Hospital
    New trial
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MET (MET proto-oncogene, receptor tyrosine kinase) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability) • RET (Ret Proto-Oncogene) • FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • NRG1 (Neuregulin 1) • VEGFA (Vascular endothelial growth factor A) • RNF43 (Ring Finger Protein 43) • TYK2 (Tyrosine Kinase 2) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF V600E • KRAS mutation • EGFR mutation • MSI-H/dMMR • HER-2 overexpression • HER-2 amplification • PIK3CA mutation • BRAF V600 • MET amplification • RET fusion • FGFR2 mutation • PALB2 mutation • FGFR2 fusion • MET mutation • IDH mutation + BRAF V600E • IDH mutation + NTRK fusion
    6d
    Torametinib for the Treatment of Recurrent/Refractory Pediatric Tumors (ChiCTR2500114659)
    P4, N=28, Not yet recruiting, The First Affiliated Hospital,Sun Yat-sen University; The First Affiliated Hospital, Sun Yat-sen University
    New P4 trial
    |
    BRAF (B-raf proto-oncogene) • NF1 (Neurofibromin 1)
    |
    BRAF V600 • RAS mutation
    |
    Loqtorzi (toripalimab-tpzi)